RXi Awarded Funding For Cancer Therapy
Westborough-based RXi Pharmaceuticals Corp. has been awarded a $300,000 grant from the National Institutes of Health to fund development of a treatment for retinoblastoma, a rare form of eye cancer.
The Small Business Innovation Research grant, by the National Cancer Institute, will provide six months of funding for the discovery and preclinical development of the therapy – sd-rxRNA – through a collaborative project between RXi and Memorial Sloan-Kettering Cancer Center.
Through the project, compounds will be developed to stop targets that are critical to the growth and survival of the cancer cells.
"We are honored to have the opportunity to collaborate with the team at Memorial Sloan-Kettering, and are very pleased to have received financial support from the NCI to further the development of our novel RNAi compounds as potential therapeutics for ocular cancer," said RXi Chief Development Officer Pamela Pavco. "The grant process is highly competitive, and this award serves to recognize and support the therapeutic potential of RXI's proprietary RNAi platform."
WBJ Web Partners
Most Recent
Most Recent
0 Comments